Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
European Society for Medical Oncology (ESMO)
ESMO 2018
ESMO 2018
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
ESMO 2018
Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer.
Read More ›
Association of PD-L1 Expression with Clinical Response to Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer
ESMO 2018
Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer.
Read More ›
A Phase 2 Trial of Combination Nivolumab and Bevacizumab in Recurrent Ovarian Cancer
ESMO 2018
This combination of antiangiogenic and immune checkpoint blockade has clinical activity in women with recurrent ovarian cancer.
Read More ›
Maintenance Olaparib Following Platinum-Based Chemotherapy in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA1/2 Mutation: Results from the Phase 3 SOLO1 Trial
ESMO 2018
Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo.
Read More ›
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
ESMO 2018
Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established.
Read More ›
The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure
ESMO 2018
In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals.
Read More ›
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
ESMO 2018
Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.
Read More ›
Initial Results from an Expansion Cohort Receiving Mirvetuximab Soravtansine/Pembrolizumab for Platinum-Resistant Ovarian Cancer: Initial Results from FORWARD II
ESMO 2018
The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity.
Read More ›
Page 2 of 2
1
2
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us